drugset / Trial / NCT05252416
(VELA) Study of BLU-222 in Advanced Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anticancer activity of BLU-222, a selective inhibitor of CDK2.
Timeline
- Start
- 2022-04-07
- Primary completion
- 2025-07-04
- Completion
- 2025-07-04
Outcome
Outcome not reported
Stopped: “This trial was terminated prior to the initiation of Phase 2 for reasons not due to safety concerns.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CERTOCICLIB | Small molecule | — | Oral |
| Subject | Carboplatin | Small molecule | — | Intravenous |
| Subject | Fulvestrant | Small molecule | — | Intramuscular |
| Subject | Ribociclib | Small molecule | — | Oral |